Press Release – For immediate release – May 09, 2017 – 17:45 CEST –
Disclosure of total number of voting rights and number of shares in the capital at April 30th, 2017, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations
| Total number of shares | 11,675,889 |
| Number of real voting rights* (excluding treasury shares) | 11,648,957 |
| Theoritical number of voting rights* (including treasury shares**) | 11,658,869 |
(*) Class E preference shares are non-voting
(**) Pursuant to article 223-11 of the AMF’s General Regulations
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.
